HELENA LABS' CK-MG TEST SENSITIVITY OF 95.7% FOR MYOCARDIAL INFARCTION
This article was originally published in The Gray Sheet
Executive SummaryHELENA LABS' CK-MG TEST SENSITIVITY OF 95.7% FOR MYOCARDIAL INFARCTION reported by Peter Puleo, MD, Baylor College of Medicine, et al. in a study published in the Sept. 1 issue of The New England Journal of Medicine. Helena Laboratories' test, which measures subforms of creatine kinase MB, is designed to overcome limitations of conventional CK-MB assays such as lengthy test time and lack of sensitivity. The traditional CK-MB test has a sensitivity of 48%, according to the NEJM report
You may also be interested in...
The World Trade Organization is not the place to discuss pharmaceutical pricing, and strong intellectual property rights do not threaten access to medicines, according to EU and US delegations to the WTO.
How do the EU’s new MDR cybersecurity guidelines expand on the MDR and fit into the myriad other software-related guidance documents the medtech industry has to consider?
Bio-Thera, which has just started selling China’s first adalimumab biosimilar rival to AbbVie’s top-selling arthritis treatment Humira, has raised $241m in an IPO on the Shanghai Stock Exchange.